MA39748A - Cenicriviroc pour le traitement de la fibrose - Google Patents

Cenicriviroc pour le traitement de la fibrose

Info

Publication number
MA39748A
MA39748A MA039748A MA39748A MA39748A MA 39748 A MA39748 A MA 39748A MA 039748 A MA039748 A MA 039748A MA 39748 A MA39748 A MA 39748A MA 39748 A MA39748 A MA 39748A
Authority
MA
Morocco
Prior art keywords
cenicriviroc
fibrosis
treatment
Prior art date
Application number
MA039748A
Other languages
English (en)
Inventor
Eric Lefebvre
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Publication of MA39748A publication Critical patent/MA39748A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7052—Fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
MA039748A 2014-03-21 2015-03-20 Cenicriviroc pour le traitement de la fibrose MA39748A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461968829P 2014-03-21 2014-03-21
US201462024713P 2014-07-15 2014-07-15
US201562114304P 2015-02-10 2015-02-10

Publications (1)

Publication Number Publication Date
MA39748A true MA39748A (fr) 2021-04-21

Family

ID=54145485

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039748A MA39748A (fr) 2014-03-21 2015-03-20 Cenicriviroc pour le traitement de la fibrose

Country Status (16)

Country Link
US (3) US20170239262A1 (fr)
EP (2) EP3119401A4 (fr)
JP (1) JP6556825B2 (fr)
KR (1) KR20160132489A (fr)
CN (1) CN106488769A (fr)
AU (2) AU2015230986A1 (fr)
BR (1) BR112016021682A2 (fr)
CA (1) CA2941411A1 (fr)
CL (1) CL2016002372A1 (fr)
HK (1) HK1232147A1 (fr)
IL (1) IL247515A0 (fr)
MA (1) MA39748A (fr)
MX (1) MX2016012262A (fr)
RU (2) RU2724339C2 (fr)
SG (2) SG11201607859SA (fr)
WO (1) WO2015143367A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2206702B1 (fr) 2001-08-08 2011-12-28 Tobira Therapeutics, Inc. Composé bicyclique, son préparation et utilisation
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
SG10201708595YA (en) * 2013-05-15 2017-11-29 Tobira Therapeutics Inc Cenicriviroc compositions and methods of making and using the same
SG10201801654RA (en) 2014-05-28 2018-04-27 Childrens Hospital Med Ct Methods and systems for converting precursor cells into gastric tissues through directed differentiation
EP3777863A1 (fr) * 2014-09-12 2021-02-17 Tobira Therapeutics, Inc. Polythérapie faisant appel au cénicriviroc pour le traitement de la fibrose
AU2015331848B2 (en) 2014-10-17 2022-03-03 Children's Hospital Medical Center, D/B/A Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
BR112017013130A2 (pt) 2014-12-23 2017-12-26 Tobira Therapeutics Inc processo de fabricação de cenicriviroc e análogos relacionados
JP2018532720A (ja) * 2015-09-16 2018-11-08 トビラ セラピューティクス， インコーポレイテッド 線維症の治療のためのセニクリビロック併用療法
US10724095B2 (en) 2015-12-16 2020-07-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic markers of immunosenescence and methods for determining the susceptibility to nosocomial infections
FR3050112B1 (fr) 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
CN109415685B (zh) 2016-05-05 2023-07-04 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
BR112018076449A2 (pt) 2016-06-21 2019-04-09 Tobira Therapeutics, Inc. cenicriviroc purificado e intermediários purificados para fazer cenicriviroc
CN106248947A (zh) * 2016-07-21 2016-12-21 中国人民解放军军事医学科学院基础医学研究所 一种哺乳动物高原脑水肿生物标志物及其应用
JP2019526628A (ja) 2016-08-31 2019-09-19 トビラ セラピューティクス， インコーポレイテッド セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス
EP4553082A3 (fr) 2016-11-04 2025-08-20 Children's Hospital Medical Center Compositions d'organoïdes hépatiques et leurs procédés de fabrication et d'utilisation
EP3548507A4 (fr) 2016-12-05 2020-07-15 Children's Hospital Medical Center Organoïdes du côlon et leurs procédés de préparation et d'utilisation
CA3051977A1 (fr) * 2017-02-24 2018-08-30 Genfit Compositions pharmaceutiques pour polytherapie
JP7248586B2 (ja) 2017-04-14 2023-03-29 チルドレンズ ホスピタル メディカル センター 複数ドナー幹細胞組成物およびそれを作製する方法
EP3694603B1 (fr) 2017-10-10 2026-04-08 Children's Hospital Medical Center Compositions de tissus oesophagiens et/ou d'organoïdes et leurs procédés de fabrication
EP3727394A4 (fr) 2017-12-21 2021-09-08 Children's Hospital Medical Center Organoïdes humains numérisés et méthodes d'utilisation de ceux-ci
US11292785B2 (en) 2018-02-02 2022-04-05 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nitrogen-containing benzoheterocycle compound comprising carboxylic acid group, preparation method and use thereof
GB201804922D0 (en) * 2018-03-27 2018-05-09 Ucl Business Plc Traatment
EP4678727A3 (fr) 2018-07-26 2026-03-11 Children's Hospital Medical Center Tissus hépato-biliaire-pancréatiques et leurs procédés de fabrication
CA3112026A1 (fr) 2018-09-12 2020-03-19 Children's Hospital Medical Center Compositions d'organoides pour la production de cellules souches hematopoietiques et leurs derives
US12600943B2 (en) 2019-02-01 2026-04-14 The University Of Hong Kong Innervated organoid compositions and methods of making same
US12497597B2 (en) 2019-05-31 2025-12-16 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
AU2020283048A1 (en) 2019-05-31 2021-12-23 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
WO2021133811A1 (fr) * 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Formes solides de cenicriviroc et leur procédé de préparation
JP2023538533A (ja) * 2020-08-07 2023-09-08 ブリストル－マイヤーズ スクイブ カンパニー 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１
US20250049840A1 (en) * 2022-01-14 2025-02-13 Dimerix Bioscience Pty Ltd Compositions comprising a chemokine receptor pathway inhibitor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2276706T3 (es) * 1999-12-08 2007-07-01 Teijin Limited Antagonistas del receptor ccr5 de aminas ciclicas.
EP2206702B1 (fr) 2001-08-08 2011-12-28 Tobira Therapeutics, Inc. Composé bicyclique, son préparation et utilisation
CH696628A5 (de) * 2002-02-26 2007-08-31 Eprova Ag Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der
JPWO2006059716A1 (ja) 2004-12-03 2008-06-05 武田薬品工業株式会社 固形製剤
JP2008542380A (ja) * 2005-05-31 2008-11-27 ノバルティス アクチエンゲゼルシャフト 鉄が病因に関与する肝臓疾患の処置
CN101511800B (zh) * 2006-07-14 2013-02-27 坎莫森特里克斯公司 三唑基苯基苯磺酰胺
US20080194575A1 (en) * 2006-10-04 2008-08-14 Naiara Beraza Treatment for non-alcoholic-steatohepatitis
CA2665808A1 (fr) * 2006-10-05 2008-05-22 Centocor Ortho Biotech Inc. Antagonistes de ccr2 pour le traitement de la fibrose
RU2337365C1 (ru) * 2006-12-12 2008-10-27 Государственное образовательное учреждение высшего профессионального образования Новосибирский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию (ГОУ ВПО НГМУ Росздрава) Способ дифференциальной диагностики алкогольного и неалкогольного стеатогепатита
RU2435593C2 (ru) * 2009-07-21 2011-12-10 Лев Давидович Раснецов Фармацевтическая композиция для лечения сахарного диабета 2 типа и лекарственное средство на его основе
SG10201708595YA (en) * 2013-05-15 2017-11-29 Tobira Therapeutics Inc Cenicriviroc compositions and methods of making and using the same

Also Published As

Publication number Publication date
CA2941411A1 (fr) 2015-09-24
HK1232147A1 (zh) 2018-01-05
EP3119401A4 (fr) 2017-12-13
US20200368247A1 (en) 2020-11-26
MX2016012262A (es) 2017-01-06
US20190099429A1 (en) 2019-04-04
RU2016141281A3 (fr) 2018-10-26
RU2016141281A (ru) 2018-04-23
BR112016021682A2 (pt) 2018-06-26
CN106488769A (zh) 2017-03-08
EP3922246A1 (fr) 2021-12-15
SG11201607859SA (en) 2016-10-28
RU2020119611A (ru) 2020-06-29
RU2724339C2 (ru) 2020-06-23
EP3119401A2 (fr) 2017-01-25
AU2015230986A1 (en) 2016-10-13
SG10201808104RA (en) 2018-10-30
CL2016002372A1 (es) 2017-02-10
JP6556825B2 (ja) 2019-08-07
JP2017509704A (ja) 2017-04-06
US20170239262A1 (en) 2017-08-24
WO2015143367A2 (fr) 2015-09-24
AU2020203867A1 (en) 2020-07-02
KR20160132489A (ko) 2016-11-18
IL247515A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
EP3374502A4 (fr) Procédés pour le traitement de dystrophies cornéennes
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
IL247452A0 (en) Compounds for treatment of complement mediated disorders
MA41449A (fr) Polythérapies pour le traitement de cancers
HUE059158T2 (hu) Eljárás pridopidin elõállítására
EP3313325A4 (fr) Échafaudages implantables pour le traitement de la sinusite
MA47558A (fr) Traitement de la fibrose
MA42999A (fr) Polythérapie pour le traitement de malignités
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
IL247857B (en) Dynamic enablement of multithreading
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3375108A4 (fr) Traitement dewlan
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome
EP4067461C0 (fr) Procédé de réduction du point d'écoulement à efficacité élevée
HUE049170T2 (hu) Eljárás szubsztituált cikloszerinek elõállítására
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
EP3349793A4 (fr) Anti-s100a8 pour le traitement de la leucémie
EP3386967A4 (fr) Combinaisons pour le traitement de calculs rénaux
EP3328384A4 (fr) Traitement de la fibrose
EP3309165A4 (fr) Agent de traitement de surface
HUE045704T2 (hu) Eljárás 5-fluor-1H-pirazolok elõállítására hexafluorpropénbõl kiindulva
EP3386593A4 (fr) Composition immunomodulatrice pour le traitement
HUE063820T2 (hu) Módszerek kardiovaszkuláris betegségek kezelésére